The evidence is mixed2 supporting, 3 against, 0 worth knowing
Supporting
trading 9% above its 200-day average
3 independent kinds of evidence agree today, which is uncommon
Against
down 4% over twelve months
revenue fell 15% year on year in the quarter ending 2026-03-31
net margin has narrowed from -14.4% to -26.2% across four quarters
Worth knowing
nothing the data supports either way
What would change this read: a close below 4,240, its 200-day average.
Assembled automatically from the figures on this page — the scans matched, their measured record, the filed financials, the derivatives positioning and the peer comparison. It is not a recommendation, no one has spoken to the company, and every claim above can be checked against a number further down this page.
How it has performed
price return over each window, measured against zero
What the scans say today
3 of 47 matched on 2026-08-21
ORISSAMINE matches 3 of the 47 scans today, across 3 different kinds of evidence. Three or more independent families agreeing is uncommon — it is the same test the shortlist on every page uses.
ORISSAMINE trades at 398× trailing earnings, above its median of 307× over this window — 30% more expensive than usual. The band runs from the 5th to the 95th percentile, so single-day spikes do not set the edges.
This window is short by the standards of valuation history — it begins where four quarters of filed earnings first exist. A stock can look cheap against two years and expensive against ten.
Other filing filings were typically -0.08pt vs the market over the next 5 sessions (n=12,093) · Board meeting filings were typically -0.04pt vs the market over the next 5 sessions (n=5,458)
The business
from the company’s filed results
Everything below is taken from the company’s own quarterly filing with the exchange — the XBRL document it submitted, not a vendor’s summary of it. Figures in rupees crore.
RevenueNet profit, drawn inside its revenue barNet margin, own scale belowrupees crore, per quarter as filed. Revenue bars start at zero.
Going for it
nothing clear in the filed numbers
Going against it
revenue fell 15% against the same quarter a year earlier
profit dropped 156% year on year
net margin narrowed from 21.1% to -26.2%
the company has not been profitable over the last four filed quarters
Quarter-by-quarter numbers, as filed
Quarter
Revenue
Profit before tax
Net profit
EPS
Net margin
Q4 FY26
2026-03-31 · standalone
29
-12
-8
—
-26.2%
Q3 FY26
2025-12-31 · standalone
21
6
4
7.24
21.1%
Q2 FY26
2025-09-30 · standalone
25
3
3
5.24
12.5%
Q1 FY26
2025-06-30 · standalone
19
-3
-3
—
-14.4%
Q3 FY25
2024-12-31 · standalone
21
-8
-7
-12.49
-36.3%
Q2 FY25
2024-09-30 · standalone
23
1
1
1.32
3.4%
Quarterly filings are unaudited unless stated. Consolidated figures are used where the company files both. A single quarter is a noisy thing — the trend across the column is worth more than the top row.
Where the price stands
the same figures every scan on this site is computed from
Trend
Distance from the averages traders watch. Above all of them is a bull phase; below the 200-day is the line most investors use to say otherwise.
Versus 50-day average+12.5%
Versus 200-day average+8.9%
Below 52-week high-20.4%
Above 52-week low+47.7%
Momentum
How hard it has been pushed lately. Above 70 on RSI is stretched, below 30 is washed out — neither is a signal on its own.
RSI (14)67.1
Higher closes in last 51 of 5
Six-month return+9.73%
Risk and liquidity
What a position costs to hold and to exit. Position sizing starts with the daily swing, not with conviction.
Typical daily swing (ATR)5.06%
Volume versus 20-day0.2x
Median daily turnoverRs 6.9 cr
Recent sessions
what this stock has matched since the engine went live
This is the live record, not the backtest — the scans this stock actually appeared in on each stored session. A name that keeps reappearing is in a persistent condition; a one-day appearance usually is not.